Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Thyroid Neoplasms 2Neoplasms 2Melanoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Skin Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Craniopharyngioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 7trametinib 5pembrolizumab 5selpercatinib 4dabrafenib 4Specimen Handling 4Nivolumab 4cabozantinib 3Iodine-131 3spartalizumab 2omipalisib 2lenvatinib 2durvalumab 2binimetinib 2Vemurafenib 2Sorafenib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1sapanisertib 1relatlimab 1regorafenib 1pertuzumab 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Neoplasms × Vemurafenib × Clear all
NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡